BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Orexigen Therapeutics, Inc. (OREX) Announces Upcoming Data Presentations at the American College of Obstetricians and Gynecologist Annual Clinical Meeting


4/26/2011 6:53:43 AM

SAN DIEGO, April 26, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) a biopharmaceutical company focused on the treatment of obesity, today announced the schedule of its upcoming Contrave® (naltrexone sustained release (SR)/bupropion SR) presentations taking place at The American College of Obstetricians and Gynecologists (The College) 59th Annual Clinical Meeting, April 30 May 4.

The College: Walter E. Washington Convention Center, Washington, DC.

Monday, May 2:

Poster Presentation

Abstract: 30

Presenter: Sandra Carson, M.D., Medical Director of Women and Infants' Center for Reproduction and Infertility and Division Director of Reproductive Endocrinology and Infertility, Women and Infants Hospital, Providence, RI

Title: "Increased Weight Loss Seen with Naltrexone SR/ Bupropion SR Combination Across Menopausal Status"

Time: 3:00-3:45 p.m. EDT

Location: Registration East


Tuesday, May 3:

Poster Presentation

Abstract: 39

Presenter: D. Yvette LaCoursiere, M.D., Assistant Professor, Department of Reproductive Medicine, University of California, San Diego

Title: "Naltrexone SR/Bupropion SR Combination Therapy Produces Weight Loss in Overweight/Obese Women"

Time: 3:00-3:45 p.m., EDT

Location: Registration East



About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product, Contrave®, has completed Phase 3 clinical trials and has received a Complete Response letter from the FDA for its New Drug Application. The Company is in the process of determining the next steps for Contrave. The Company's second product, Empatic, has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at www.orexigen.com.

SOURCE Orexigen Therapeutics, Inc.


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->